Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Vinay Sundaram & Kris V Kowdley. (2016) Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection. Hepatic Medicine: Evidence and Research 8, pages 75-80.
Read now
Read now
Vinay Sundaram & Kris V. Kowdley. (2016) Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection. Expert Review of Gastroenterology & Hepatology 10:1, pages 13-20.
Read now
Read now
Articles from other publishers (28)
Hemlata M. NIMJE, Smita J. PAWAR & Meenakshi N. DEODHAR. (2023) Validated Stability-Indicating RP-HPLC Method for Daclatasvir in Tablets. Turkish Journal of Pharmaceutical Sciences 20:4, pages 218-225.
Crossref
Crossref
Christina Sølund, Martin S. Pedersen, Ulrik Fahnøe, Jonathan Filskov, Håvard Jenssen, Nina Weis, Kristian Schønning & Jens Bukh. (2023)
Pre‐existing, treatment‐specific resistance‐associated substitutions in hepatitis C virus genotype 1 and 3 and viral
RNA
titers during treatment with direct‐acting antivirals
. APMIS 131:8, pages 426-433.
Crossref
Crossref
Ahmed S Fayed, Maha A Hegazy, Ebraam B Kamel & Maya S Eissa. (2022) Three Smart and Original Spectrophotometric Data Processing Ratio Techniques for Resolving the Partial Overlapped Spectra of the Binary Antiviral Mixture Daclatasvir/Sofosbuvir: Application to Combined Dosage Form Darvoni® Tablets. Journal of AOAC INTERNATIONAL 105:2, pages 612-622.
Crossref
Crossref
Dong Lin, Venu Reddy, Hanadi Osman, Adriana Lopez, Ali Riza Koksal, Sadeq Mutlab Rhadhi, Srikanta Dash & Yucel Aydin. (2021) Additional Inhibition of Wnt/β-Catenin Signaling by Metformin in DAA Treatments as a Novel Therapeutic Strategy for HCV-Infected Patients. Cells 10:4, pages 790.
Crossref
Crossref
Hemlata M. Nimie & Minakshi N. Deodhar. (2020) Method Development and Force Degradation Study for Daclatasvir Using LC-MS/MS. Method Development and Force Degradation Study for Daclatasvir Using LC-MS/MS.
Mortada El-Shabrawi & Fetouh Hassanin. (2019) Paediatric hepatitis C virus infection and its treatment: Present, past, and future. Arab Journal of Gastroenterology 20:3, pages 163-174.
Crossref
Crossref
Varaprasad Jagadabi, P V Nagendra kumar, Kasthuri Mahesh, Srinivasu Pamidi, L A Ramaprasad & D Nagaraju. (2019) A Stability-Indicating UPLC Method for the Determination of Potential Impurities and Its Mass by a New QDa Mass Detector in Daclatasvir Drug Used to Treat Hepatitis C Infection. Journal of Chromatographic Science 57:1, pages 44-53.
Crossref
Crossref
Wafaa S. Hassan, Manal S. Elmasry, Heba M. Elsayed & Dalia W. Zidan. (2018) Comparative study of six sequential spectrophotometric methods for quantification and separation of ribavirin, sofosbuvir and daclatasvir: An application on Laboratory prepared mixture, pharmaceutical preparations, spiked human urine, spiked human plasma, and dissolution test. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 202, pages 159-173.
Crossref
Crossref
Dalia W. Zidan, Wafaa S. Hassan, Manal S. Elmasry & Abdalla A. Shalaby. (2018) Investigation of anti-Hepatitis C virus, sofosbuvir and daclatasvir, in pure form, human plasma and human urine using micellar monolithic HPLC-UV method and application to pharmacokinetic study. Journal of Chromatography B 1086, pages 73-81.
Crossref
Crossref
K. Rajender Reddy, Stanislas Pol, Paul J. Thuluvath, Hiromitsu Kumada, Joji Toyota, Kazuaki Chayama, James Levin, Eric J. Lawitz, Adrian Gadano, Wayne Ghesquiere, Guido Gerken, Maurizia R. Brunetto, Cheng‐Yuan Peng, Marcelo Silva, Simone I. Strasser, Jeong Heo, Fiona McPhee, Zhaohui Liu, Rong Yang, Misti Linaberry & Stephanie Noviello. (2017) Long‐term follow‐up of clinical trial patients treated for chronic HCV infection with daclatasvir‐based regimens. Liver International 38:5, pages 821-833.
Crossref
Crossref
O. Tronina, K. Ślubowska, N. Mikołajczyk-Korniak, E. Komuda-Leszek, R. Wieczorek-Godlewska, B. Łągiewska, M. Pacholczyk, W. Lisik, M. Kosieradzki & M. Durlik. (2017) Fibrosing Cholestatic Hepatitis C After Liver Transplantation: Therapeutic Options Before and After Introduction of Direct-Acting Antivirals: Our Experience and Literature Review. Transplantation Proceedings 49:6, pages 1409-1418.
Crossref
Crossref
Ayman Geddawy, Yasmine F. Ibrahim, Nabil M. Elbahie & Mohammad A. Ibrahim. (2017) Direct acting anti-hepatitis C virus drugs: Clinical pharmacology and future direction. Journal of Translational Internal Medicine 5:1, pages 8-17.
Crossref
Crossref
Robert FlisiakSeiji KawazoeOlga ZnoykoNimer AssyAdrian GadanoJia-Horng KaoKwan-Sik LeeRicardo ZwirtesSimon PortsmouthYuping DongDong XuHiromitsu KumadaSubasree Srinivasan. (2016) Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b. Journal of Interferon & Cytokine Research 36:11, pages 635-643.
Crossref
Crossref
Phil McEwan, Thomas Ward, Samantha Webster, Yong Yuan, Anupama Kalsekar, Isao Kamae, Masahiro Kobayashi, Ann Tang & Hiromitsu Kumada. (2016) Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b. Hepatology Research 46:5, pages 423-433.
Crossref
Crossref
Javier Ampuero. (2016) Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options. World Journal of Gastroenterology 22:22, pages 5285.
Crossref
Crossref
Odile Petsaris, Sophie Vallet, Hélène Le Guillou-Guillemette, Pascal Veillon, Stéphanie Gouriou, Georges Barbier, Jean-Baptiste Nousbaum, Philippe Saliou, Gisèle NKontchou, Jean-Claude Trinchet, Francoise Lunel-Fabiani & Christopher Payan. (2016) Duplication of the V3 domain in hepatitis C virus (1b) NS5A protein: Clonal analysis and physicochemical properties related to hepatocellular carcinoma occurrence. Journal of Clinical Virology 74, pages 19-25.
Crossref
Crossref
Javier Ampuero & Manuel Romero-G?mez. (2015) Hepatitis C Virus. Gastroenterology Clinics of North America 44:4, pages 845-857.
Crossref
Crossref
Paul Y Kwo & Maaz B. Badshah. (2015) Treatment of HCV in Patients who Failed First-Generation PI Therapy: a Review of Current Literature. Current Gastroenterology Reports 17:10.
Crossref
Crossref
C. Bunchorntavakul & K. R. Reddy. (2015) Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection. Alimentary Pharmacology & Therapeutics 42:3, pages 258-272.
Crossref
Crossref
Il Hak Bae, Hee Sun Kim, Youngsu You, Chieyeon Chough, Weonu Choe, Min Kyung Seon, Seung Gi Lee, Gyochang Keum, Sung Key Jang & B. Moon Kim. (2015) Novel benzidine and diaminofluorene prolinamide derivatives as potent hepatitis C virus NS5A inhibitors. European Journal of Medicinal Chemistry 101, pages 163-178.
Crossref
Crossref
Peter Hauser. (2015) Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications. World Journal of Hepatology 7:15, pages 1921.
Crossref
Crossref
Vasilios Papastergiou. (2015) Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6. World Journal of Clinical Cases 3:3, pages 210.
Crossref
Crossref
Tomomi Furihata, Shogo Matsumoto, Zhongguo Fu, Akihito Tsubota, Yuchen Sun, Sayaka Matsumoto, Kaoru Kobayashi & Kan Chiba. (2014) Different Interaction Profiles of Direct-Acting Anti-Hepatitis C Virus Agents with Human Organic Anion Transporting Polypeptides. Antimicrobial Agents and Chemotherapy 58:8, pages 4555-4564.
Crossref
Crossref
Makonen Belema & Nicholas A. Meanwell. (2014) Discovery of Daclatasvir, a Pan-Genotypic Hepatitis C Virus NS5A Replication Complex Inhibitor with Potent Clinical Effect. Journal of Medicinal Chemistry 57:12, pages 5057-5071.
Crossref
Crossref
Phil McEwan, Thomas Ward, Samantha Webster, Yong Yuan, Anupama Kalsekar, Kristine Broglio, Isao Kamae, Melanie Quintana, Scott M. Berry, Masahiro Kobayashi, Sachie Inoue, Ann Tang & Hiromitsu Kumada. (2014) Estimating the Long-Term Clinical and Economic Outcomes of Daclatasvir Plus Asunaprevir in Difficult-to-Treat Japanese Patients Chronically Infected with Hepatitis C Genotype 1b. Value in Health Regional Issues 3, pages 136-145.
Crossref
Crossref
J. Ampuero, M. Romero-Gómez & K. R. Reddy. (2014) Review article: HCV genotype 3 - the new treatment challenge. Alimentary Pharmacology & Therapeutics 39:7, pages 686-698.
Crossref
Crossref
Makonen Belema, Van N. Nguyen, Carol Bachand, Dan H. Deon, Jason T. Goodrich, Clint A. James, Rico Lavoie, Omar D. Lopez, Alain Martel, Jeffrey L. Romine, Edward H. Ruediger, Lawrence B. Snyder, Denis R. St. Laurent, Fukang Yang, Juliang Zhu, Henry S. Wong, David R. Langley, Stephen P. Adams, Glenn H. Cantor, Anjaneya Chimalakonda, Aberra Fura, Benjamin M. Johnson, Jay O. Knipe, Dawn D. Parker, Kenneth S. Santone, Robert A. Fridell, Julie A. Lemm, Donald R. O’BoyleIIII, Richard J. Colonno, Min Gao, Nicholas A. Meanwell & Lawrence G. Hamann. (2014) Hepatitis C Virus NS5A Replication Complex Inhibitors: The Discovery of Daclatasvir. Journal of Medicinal Chemistry 57:5, pages 2013-2032.
Crossref
Crossref
Makonen Belema, Omar D. Lopez, John A. Bender, Jeffrey L. Romine, Denis R. St. Laurent, David R. Langley, Julie A. Lemm, Donald R. O’BoyleIIII, Jin-Hua Sun, Chunfu Wang, Robert A. Fridell & Nicholas A. Meanwell. (2014) Discovery and Development of Hepatitis C Virus NS5A Replication Complex Inhibitors. Journal of Medicinal Chemistry 57:5, pages 1643-1672.
Crossref
Crossref